UNITED THERAPEUTICS (UTHR) CFO sells 8,750 shares after exercising options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 8,750 shares of common stock at an exercise price of $146.03 per share and sold 8,750 shares in open‑market transactions on June 22, 2026. The sales were executed at weighted average prices around the mid‑$530s to low‑$540s per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly holds 18,876 shares of UNITED THERAPEUTICS common stock.
Positive
- None.
Negative
- None.
Insights
CFO executed options and sold matching shares under a pre‑planned Rule 10b5‑1 program.
CFO and Treasurer James Edgemond exercised stock options to acquire 8,750 UNITED THERAPEUTICS common shares at an exercise price of $146.03 and sold 8,750 shares in multiple open‑market trades around the mid‑$530s to low‑$540s per share.
The filing states the exercise and subsequent sales were made under a Rule 10b5‑1 trading plan entered on October 31, 2025, indicating the trades were pre‑scheduled rather than opportunistic. After these transactions, Edgemond holds 18,876 shares directly, and this option grant appears fully exercised with no remaining position from it.
Insider Trade Summary 10b5-1
Net Seller: 8,750 shares ($4,708,786)
Net Sell
10 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
8,750 shs ($4.71M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,750 | $0.00 | -- |
| Exercise | Common Stock | 8,750 | $146.03 | $1.28M |
| Sale | Common Stock | 164 | $534.0595 | $88K |
| Sale | Common Stock | 865 | $534.9849 | $463K |
| Sale | Common Stock | 1,091 | $536.0466 | $585K |
| Sale | Common Stock | 840 | $537.1829 | $451K |
| Sale | Common Stock | 2,266 | $538.234 | $1.22M |
| Sale | Common Stock | 1,994 | $539.1301 | $1.08M |
| Sale | Common Stock | 280 | $539.8261 | $151K |
| Sale | Common Stock | 1,250 | $541.25 | $677K |
Holdings After Transaction:
Stock Option — 0 shares (Direct, null);
Common Stock — 27,626 shares (Direct, null)
Footnotes (1)
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 8,750 shares
Shares acquired via option exercise: 8,750 shares
Option exercise price: $146.03 per share
+5 more
8 metrics
Shares sold
8,750 shares
Total common shares sold in open-market transactions on June 22, 2026
Shares acquired via option exercise
8,750 shares
Common shares received from exercising stock options on June 22, 2026
Option exercise price
$146.03 per share
Exercise price for 8,750 stock option shares
Reported sale price (example)
$541.25 per share
One weighted average price for common stock sale on June 22, 2026
Post-transaction holdings
18,876 shares
Direct UNITED THERAPEUTICS common stock held by CFO after transactions
Rule 10b5-1 plan date
October 31, 2025
Date CFO entered trading plan covering these transactions
Option vesting date
March 15, 2020
Exercise date stated for stock options used in this transaction
Option expiration date
March 15, 2027
Original expiration date for the exercised stock options
Key Terms
Rule 10b5-1 trading plan, open-market sale, stock options, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did UNITED THERAPEUTICS (UTHR) disclose for CFO James Edgemond?
The filing shows CFO James Edgemond exercised stock options for 8,750 UNITED THERAPEUTICS shares at $146.03 and sold 8,750 shares in open‑market trades around the mid‑$530s to low‑$540s per share on June 22, 2026.
Were the UNITED THERAPEUTICS (UTHR) CFO’s stock sales made under a Rule 10b5-1 plan?
Yes. The footnotes state the option exercise and subsequent sale of UNITED THERAPEUTICS shares occurred pursuant to a Rule 10b5‑1 trading plan that James Edgemond entered on October 31, 2025, indicating the transactions were pre‑arranged rather than timed discretionarily.
What stock option terms applied to the UNITED THERAPEUTICS (UTHR) CFO’s exercised options?
The CFO exercised stock options covering 8,750 underlying UNITED THERAPEUTICS common shares at a conversion or exercise price of $146.03 per share. The options became exercisable on March 15, 2020 and had an expiration date of March 15, 2027 before this exercise.